Leerink Partnrs Has Pessimistic Outlook of RVMD Q3 Earnings

Revolution Medicines, Inc. (NASDAQ:RVMD) – Research analysts at Leerink Partnrs decreased their Q3 2025 earnings per share (EPS) estimates for Revolution Medicines in a note issued to investors on Wednesday, August 6th. Leerink Partnrs analyst J. Chang now expects that the company will earn ($1.45) per share for the quarter, down from their prior estimate of ($1.07). The consensus estimate for Revolution Medicines’ current full-year earnings is ($3.49) per share. Leerink Partnrs also issued estimates for Revolution Medicines’ Q4 2025 earnings at ($1.61) EPS, FY2025 earnings at ($5.50) EPS and FY2026 earnings at ($5.25) EPS.

Revolution Medicines (NASDAQ:RVMD) last issued its earnings results on Wednesday, August 6th. The company reported ($1.31) EPS for the quarter, missing the consensus estimate of ($0.94) by ($0.37). During the same quarter in the prior year, the business posted ($0.81) EPS. The company’s quarterly revenue was up .0% compared to the same quarter last year.

Several other equities research analysts also recently commented on the stock. Wedbush restated an “outperform” rating and issued a $73.00 target price (up previously from $67.00) on shares of Revolution Medicines in a research note on Tuesday, June 24th. Guggenheim restated a “buy” rating and issued a $80.00 target price on shares of Revolution Medicines in a research note on Wednesday, June 25th. Oppenheimer boosted their target price on shares of Revolution Medicines from $70.00 to $75.00 and gave the company an “outperform” rating in a research note on Thursday, May 8th. HC Wainwright restated a “buy” rating and issued a $72.00 target price (down from $73.00) on shares of Revolution Medicines in a research note on Wednesday, May 14th. Finally, The Goldman Sachs Group assumed coverage on Revolution Medicines in a research note on Tuesday, July 15th. They issued a “buy” rating and a $65.00 target price for the company. Eleven analysts have rated the stock with a buy rating, According to MarketBeat.com, Revolution Medicines has a consensus rating of “Buy” and a consensus target price of $68.82.

Revolution Medicines Stock Up 0.1%

Shares of NASDAQ:RVMD opened at $35.00 on Monday. Revolution Medicines has a 52 week low of $29.17 and a 52 week high of $62.40. The company has a debt-to-equity ratio of 0.13, a quick ratio of 11.79 and a current ratio of 11.79. The company’s fifty day moving average is $38.42 and its 200-day moving average is $38.74. The company has a market capitalization of $6.54 billion, a PE ratio of -7.78 and a beta of 1.16.

Institutional Trading of Revolution Medicines

Hedge funds and other institutional investors have recently made changes to their positions in the business. Boxer Capital Management LLC bought a new position in Revolution Medicines in the fourth quarter valued at about $187,184,000. Janus Henderson Group PLC boosted its holdings in Revolution Medicines by 54.5% in the fourth quarter. Janus Henderson Group PLC now owns 9,483,999 shares of the company’s stock valued at $414,777,000 after acquiring an additional 3,346,755 shares during the last quarter. Lunate Capital Ltd bought a new position in Revolution Medicines in the first quarter valued at about $77,658,000. Farallon Capital Management LLC boosted its holdings in Revolution Medicines by 17.1% in the fourth quarter. Farallon Capital Management LLC now owns 13,248,692 shares of the company’s stock valued at $579,498,000 after acquiring an additional 1,931,000 shares during the last quarter. Finally, T. Rowe Price Investment Management Inc. bought a new position in Revolution Medicines in the first quarter valued at about $59,173,000. 94.34% of the stock is currently owned by institutional investors and hedge funds.

Revolution Medicines Company Profile

Revolution Medicines, Inc, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company’s research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.